keyword
MENU ▼
Read by QxMD icon Read
search

DAA

keyword
https://www.readbyqxmd.com/read/28230928/reactivation-of-hepatitis-b-in-patients-of-chronic-hepatitis-c-with-hepatitis-b-virus-infection-treated-with-direct-acting-antivirals
#1
Ming-Lun Yeh, Chung-Feng Huang, Meng-Hsuan Hsieh, Yu-Min Ko, Kuan-Yu Chen, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ching-I Huang, Jee-Fu Huang, Po-Lin Kuo, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang
BACKGROUND AND AIMS: Hepatitis B virus (HBV) may reactivate when treating chronic hepatitis C (CHC) with direct acting antivirals (DAA). We aim to investigate the risk of HBV reactivation during DAA therapy. METHODS: CHC patients receiving pan-oral DAA therapy from Dec. 2013 to Aug. 2016 were evaluated. Fifty-seven patients that had a past HBV infection (negative hepatitis B surface antigen (HBsAg)) and positive hepatitis B core antibody (Anti-HBc)) and 7 patients that had a current HBV infection (positive HBsAg) were enrolled...
February 23, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28230455/outcomes-of-pharmacy-led-hepatitis-c-direct-acting-antiviral-utilization-management-at-a-veterans-affairs-medical-center
#2
Sendra Yang, Rachel B Britt, Mohamed G Hashem, Jamie N Brown
BACKGROUND: The Veterans Affairs Health (VA) Administration has reported hepatitis C virus (HCV) infection rates among veterans to be twice that of the general U.S population. New HCV direct-acting antiviral (DAA) treatment options offer superior sustained virologic response (SVR) rates, improved side-effect profiles, and shortened treatment courses; yet, these new HCV DAAs are expensive, and utilization management strategies are needed to optimize use and improve clinical outcomes. A VA medical center uses pharmacist-led HCV DAA utilization management strategies that includes clinical guidance, optimizing operational flow, budget tracking and forecasting, and patient outcomes tracking...
March 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28224352/hcv-management-in-resource-constrained-countries
#3
REVIEW
Seng Gee Lim
With the arrival of all-oral directly acting antiviral (DAA) therapy with high cure rates, the promise of hepatitis C virus (HCV) eradication is within closer reach. The availability of generic DAAs has improved access to countries with constrained resources. However, therapy is only one component of the HCV care continuum, which is the framework for HCV management from identifying patients to cure. The large number of undiagnosed HCV cases is the biggest concern, and strategies to address this are needed, as risk factor screening is suboptimal, detecting <20% of known cases...
February 21, 2017: Hepatology International
https://www.readbyqxmd.com/read/28222681/the-need-for-treatment-scale-up-to-impact-hcv-transmission-in-people-who-inject-drugs-in-montr%C3%A3-al-canada-a-modelling-study
#4
Anthony Cousien, Pascale Leclerc, Carole Morissette, Julie Bruneau, Élise Roy, Viet Chi Tran, Yazdan Yazdanpanah, Joseph Cox
BACKGROUND: HCV transmission remains high in people who inject drugs (PWID) in Montréal. New direct-acting antivirals (DAAs), highly effective and more tolerable than previous regimens, make a "Treatment as Prevention" (TasP) strategy more feasible. This study assesses how improvements in the cascade of care could impact hepatitis C burden among PWID in Montréal. METHODS: We used a dynamic model to simulate HCV incidence and prevalence after 10 years, and cirrhosis complications after 10 and 40 years...
February 21, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28220512/sofosbuvir-velpatasvir-voxilaprevir-with-or-without-ribavirin-in-daa-experienced-patients-with-genotype-1-hcv
#5
Eric Lawitz, Fred Poordad, Jennifer Wells, Robert H Hyland, Yin Yang, Hadas Dvory-Sobol, Luisa M Stamm, Diana M Brainard, John G McHutchison, Carmen Landaverde, Julio Gutierrez
: The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who fail direct-acting antiviral (DAA)-based regimens remains unknown. In this phase 2, open-label study conducted at a single center in the United States, patients with HCV genotype 1 infection who previously failed to achieve sustained virologic response on a DAA-based regimen were randomized to receive treatment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin for 12 weeks...
February 21, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28219772/evidence-based-recommendations-on-the-management-of-extrahepatic-manifestations-of-chronic-hepatitis-c-virus-infection
#6
REVIEW
Manuel Ramos-Casals, Anna Linda Zignego, Clodoveo Ferri, Pilar Brito-Zerón, Soledad Retamozo, Milvia Casato, Peter Lamprecht, Alessandra Mangia, David Saadoun, Athanasios G Tzioufas, Zobair M Younossi, Patrice Cacoub
∗The current therapeutic armamentarium against HCV has been recently expanded with an explosion of new molecules (DAAs) with high virological efficacy ∗The objective of this international consensus is to provide therapeutic recommendations for HCV patients with extrahepatic manifestations (EHM). ∗The use of non-antiviral therapeutic approaches should be evaluated according to the type of EHM and severity of the clinical presentation ∗B cell depletion with rituximab is the established biologic approach to cryoglobulinaemic vasculitis (CV) employed to date...
February 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28213381/outcomes-of-treatment-with-direct-acting-antivirals-for-infection-with-hepatitis-c-virus-genotypes-1-4-in-an-ambulatory-care-setting
#7
Timothy A Bach, Kathy Zaiken
PURPOSE: Outcomes with direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) genotypes 1-4 were determined. METHODS: A total of 360 patients at 36 clinical sites in Massachusetts with HCV genotypes 1-4 and a prescription for at least one DAA medication between May 2011 and October 2015 were included. The primary investigator completed a retrospective and concurrent chart review, and data were collected through April 2016. RESULTS: A total of 446 patients were assessed for eligibility into the study, with 86 patients excluded...
March 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28212220/hcv-antiviral-therapy-in-liver-transplant-candidates-and-recipients-with-renal-insufficiency
#8
Elizabeth C Verna, Robert S Brown
Hepatitis C virus (HCV) remains the leading indication for liver transplant in much of the world, and has traditionally been associated with diminished posttransplant survival due to recurrent HCV-related liver disease. This field has been dramatically changed by the advent of safe and effective directly active antiviral (DAA) therapy, such that most patients can be cured in the pre or posttransplant setting. In addition, there are now DAA regimens specifically approved for use in patients with severe renal insufficiency...
February 16, 2017: Transplantation
https://www.readbyqxmd.com/read/28206681/hepatitis-b-reactivation-in-patients-with-chronic-hepatitis-c-undergoing-anti-viral-therapy-with-an-interferon-free-regimen
#9
M-C Londoño, S Lens, Z Mariño, M Bonacci, X Ariza, T Broquetas, A Pla, C Bartres, M V Adriani, S Rodríguez-Tajes, J Costa, J A Carrión, S Pérez-Del-Pulgar, X Forns
BACKGROUND: A few cases of hepatitis B virus (HBV) reactivation during anti-viral therapy against hepatitis C (HCV) have been reported. However, the information regarding the real impact of this phenomenon is scarce. AIM: To evaluate the risk of HBV reactivation during anti-viral therapy against HCV with an interferon-free regimen with direct-acting anti-virals (DAAs). METHODS: Observational and prospective study of 352 patients receiving DAAs therapy between September 2015 and May 2016...
February 16, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28203284/novel-emerging-treatments-for-hepatitis-c-infection-a-fast-moving-pipeline
#10
REVIEW
Ara A Kardashian, Paul J Pockros
Advances in the treatment of chronic hepatitis C has been one of the pinnacles of medical science in the last 25 years. The age of direct-acting antivirals (DAAs) has led to cure rates >95% with shorter duration and low toxicity regimens, thus changing the landscape of the era of pegylated interferon and ribavirin (RBV). However, there remain some challenges with these therapies as there are multiple regimens available with a fair amount of sophistication required to administer them. Treatment continues to require knowledge of prior treatment status, viral genotype and fibrosis assessment, thus affording an opportunity for improvement in future regimens...
February 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28199517/real-world-effectiveness-of-daa-therapies-in-hiv-hcv-co-infection-996-veterans-can-t-be-wrong
#11
Mary Jane Burton, Susanna Naggie
No abstract text is available yet for this article.
February 11, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28198349/impact-of-itpa-gene-polymorphisms-on-the-risk-of-ribavirin-induced-haemolytic-anaemia-using-interferon-free-antivirals-for-chronic-hepatitis-c
#12
Isabella Esposito, Laura Benítez-Gutiérrez, Ana Treviño, Ana Arias, Maria Jesus Citores, Silvia Requena, Vicente Soriano, Valentín Cuervas-Mons, Carmen de Mendoza
BACKGROUND: Single nucleotide polymorphisms (SNPs) at the ITPA gene are associated with hemolytic anemia in chronic hepatitis C patients treated with peginterferon-ribavirin (RBV). Information in patients treated with interferon-free, direct-acting antivirals (DAA) is scarce. METHODS: Median hemoglobin (Hb) levels were compared at baseline and at week 4, when ribavirin concentration achieves steady state, in all consecutive chronic hepatitis C patients treated with oral DAA plus RBV at our clinic...
February 15, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28196130/ongoing-liver-inflammation-in-patients-with-chronic-hepatitis-c-and-sustained-virological-response
#13
Christoph Welsch, Mira Efinger, Michael von Wagner, Eva Herrmann, Stefan Zeuzem, Tania M Welzel, Christian M Lange
BACKGROUND: Novel direct-acting antiviral DAA combination therapies tremendously improved sustained virologic response (SVR) rates in patients with chronic HCV infection. SVR is typically accompanied by normalization of liver enzymes, however, hepatic inflammation, i.e. persistently elevated aminotransferase levels may persist despite HCV eradication. Aim: To investigate prevalence and risk factors for ongoing hepatic inflammation after SVR in two large patient cohorts. METHODS: This post-hoc analysis was based on prospectively collected demographic and clinical data from 834 patients with SVR after HCV treatment with either PegIFN- or DAA-based treatment regimens from the PRAMA trial (n = 341) or patients treated at our outpatient clinic (n = 493)...
2017: PloS One
https://www.readbyqxmd.com/read/28195877/direct-acting-antivirals-are-effective-for-chronic-hepatitis-c-treatment-in-elderly-patients-a-real-world-study-of-17%C3%A2-487-patients
#14
Feng Su, Lauren A Beste, Pamela K Green, Kristin Berry, George N Ioannou
BACKGROUND: The mean age of patients with chronic hepatitis C virus (HCV) infection in the USA has been increasing. Despite the increasing proportion of HCV-infected elderly patients, this group is under-represented in clinical trials of HCV treatment. AIM: We aimed to describe the real-world effectiveness of direct-acting antivirals (DAAs) among elderly patients. PATIENTS AND METHODS: We retrospectively identified 17 487 HCV-infected patients who were started on treatment with sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir-based regimens in the Veterans Affairs Healthcare System between 1 January 2014 and 30 June 2015...
February 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28195337/hepatitis-b-reactivation-in-hepatitis-b-and-c-coinfected-patients-treated-with-antiviral-agents-a-systematic-review-and-meta-analysis
#15
Guofeng Chen, Cheng Wang, Jing Chen, Dong Ji, Yudong Wang, Vanessa Wu, J Karlberg, George Lau
: There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan-oral direct-acting antivirals (DAAs). We performed a systematic review and meta-analysis to compare the rate of HBV reactivation in CHC patients coinfected with overt HBV (hepatitis B surface antigen [HBsAg] positive) and occult HBV (HBsAg negative with positive HBV DNA) infection separately, treated with interferon (IFN)-based therapy to those with pan-oral DAAs...
February 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28193659/oligonucleotide-lipid-conjugates-forming-g-quadruplex-structures-are-potent-and-pangenotypic-hepatitis-c-virus-entry-inhibitors-in-vitro-and-ex-vivo
#16
George Koutsoudakis, Alexia Paris de León, Carolina Herrera, Marcus Dorner, Gemma Pérez-Vilaró, Sébastien Lyonnais, Santiago Grijalvo, Ramon Eritja, Andreas Meyerhans, Gilles Mirambeau, Juana Díez
An HCV epidemic affecting HIV-infected men who have sex with men (MSM) is expanding worldwide. Albeit the improved cure rates obtained with the new direct-acting antiviral drug (DAA) combinations, the high rate of reinfection within this population calls urgently for novel preventive interventions. Here we show in cell culture and ex vivo experiments with human colorectal tissue that lipoquads, G-quadruplex DNA structures fused to cholesterol, are efficient HCV pangenotypic entry and cell-to-cell transmission inhibitors...
February 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28193466/three-dimensional-ionic-liquid-functionalized-magnetic-graphene-oxide-nanocomposite-for-the-magnetic-dispersive-solid-phase-extraction-of-16-polycyclic-aromatic-hydrocarbons-in-vegetable-oils
#17
Yun Zhang, Hua Zhou, Zhe-Hua Zhang, Xiang-Lun Wu, Wei-Guo Chen, Yan Zhu, Chun-Fu Fang, Yong-Gang Zhao
In this paper, a novel three-dimensional ionic liquid functionalized magnetic graphene oxide nanocomposite (3D-IL@mGO) was prepared, and used as an effective adsorbent for the magnetic dispersive solid phase extraction (MSPE) of 16 polycyclic aromatic hydrocarbons (PAHs) in vegetable oil prior to gas chromatography-mass spectrometry (GC-MS). The properties of 3D-IL@mGO were characterized by scanning electron micrographs (SEM), X-ray photoelectron spectroscopy (XPS), vibrating sample magnetometer (VSM). The 3D-IL@mGO, functionalized by ionic liquid, exhibited high adsorption toward PAHs...
February 8, 2017: Journal of Chromatography. A
https://www.readbyqxmd.com/read/28192235/high-hcv-subtype-heterogeneity-in-a-chronically-infected-general-population-revealed-by-high-resolution-hcv-subtyping
#18
Francisco Rodriguez-Frias, Leonardo Nieto, Josep Gregori, Damir Garcia-Cehic, Rosario Casillas, David Tabernero, Maria Homs, Maria Blasi, Marta Vila, Qian Chen, Victor Vargas, Lluís Castells, Lluís Viladomiu, Joan Genesca, Beatriz Minguez, Salvador Augustin, Judit Carbonell, Celia Perales, Maria Eugenia Soria, Miriam Asensio, Meritxell Llorens, Laura Ordeig, Cristina Godoy, Maria Buti, Rafael Esteban, Tomas Pumarola, Juan Ignacio Esteban, Josep Quer
OBJECTIVES: Accurately characterize the chronically-infected general HCV population in the Barcelona area by a highly sensitive subtyping method able to identify the 67 recognized hepatitis C virus (HCV) subtypes, and to discriminate mixed infections in a single individual. This information has strong implications on patient management, in deciding the optimal combination of direct-acting antivirals (DAAs) for each patient. METHODS: HCV subtyping by UDPS. All HCV patients who attended Vall d'Hebron Hospital outpatient clinics from February 2015 to May 2016 (N=1473) were included...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28191032/safety-of-new-daas-for-chronic-hcv-infection-in-a-real-life-experience-role-of-a-surveillance-network-based-on-clinician-and-hospital-pharmacist
#19
A Nappi, A Perrella, P Bellopede, A Lanza, A Izzi, M Spatarella, C Sbreglia
BACKGROUND: Direct Antiviral Agents (DAAs) for HCV therapy represents a step ahead in the cure of chronic hepatitis C. Notwithstanding the promising results in several clinical trials, few data are available on adverse effects in real life settings. METHODS: We have evaluated 170 patients with persistent infection and on those eligible to treatment we have followed up them through a network managed by clinician and hospital pharmacist. RESULTS: According to our data we have found that 41% (32 out of 78) of enrolled patients experienced adverse reactions, of these 40% were in those under 65 years while 60% was in patients older than 65 years, SVR was achieved in 88% of the patients (including drop-out)...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28187751/efficacy-safety-and-pharmacokinetics-of-simeprevir-and-tmc647055-ritonavir-with-or-without-ribavirin-and-jnj-56914845-in-hcv-genotype-1-infection
#20
RANDOMIZED CONTROLLED TRIAL
Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M Schattenberg, Peter Buggisch, Sven Francque, Leen Vijgen, Thomas N Kakuda, Eva Hoeben, Donghan Luo, An Vandebosch, Bert Jacquemyn, Pieter Van Remoortere, René Verloes
BACKGROUND: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naïve and prior-relapse patients. METHODS: The study comprised four 12-week treatment panels: Panel 1 (n = 10; GT1a) and Panel 2-Arm 1 (n = 12; GT1b): simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day; Panel 2-Arm 2 (n = 9; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1: n = 22; GT1a/GT1b) or 60 mg once daily (Arm 2: n = 22; GT1a/GT1b)...
February 10, 2017: BMC Gastroenterology
keyword
keyword
68491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"